News from GW Pharmaceuticals plc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Dec 29, 2017, 07:08 ET GW Pharmaceuticals dépose une demande d'autorisation de mise sur le marché pour Epidiolex® (cannabidiol) dans le traitement du syndrome de Lennox-Gastaut et du syndrome de Dravet

GW Pharmaceuticals plc (Nasdaq : GWPH, « GW » ou « la société »), une société biopharmaceutique spécialisée dans la recherche, le développement et...


Dec 29, 2017, 07:05 ET GW Pharmaceuticals reicht europäischen Antrag auf Marktzulassung für Epidiolex® (Cannabidiol) zur Behandlung von Lennox-Gastaut-Syndrom und Dravet-Syndrom ein

GW Pharmaceuticals plc (Nasdaq: GWPH, "GW" oder "das Unternehmen"), ein biopharmazeutisches Unternehmen, das sich auf die Erforschung, Entwicklung...


Dec 29, 2017, 07:00 ET GW Pharmaceuticals envía solicitud de autorización de comercialización en Europa para Epidiolex®

- GW Pharmaceuticals envía solicitud de autorización de comercialización en Europa para Epidiolex® (cannabidiol) en el...


Dec 29, 2017, 07:00 ET GW Pharmaceuticals presenta in Europa la richiesta di autorizzazione alla commercializzazione di Epidiolex® (cannabidiolo) nella terapia delle sindromi di Lennox-Gastaut e Dravet

GW Pharmaceuticals plc (Nasdaq: GWPH, "GW" o "l'Azienda"), un'azienda biofarmaceutica incentrata sulla scoperta, lo sviluppo e la...


May 25, 2017, 03:00 ET GW Pharmaceuticals et sa filiale américaine Greenwich Biosciences, annoncent la publication d'une étude révolutionnaire sur Epidiolex® (cannabidiol), dans The New England Journal of Medicine

- L'élaboration pharmaceutique du cannabidiol a considérablement réduit la fréquence des crises convulsives chez les enfants utilisant de...


May 25, 2017, 03:00 ET GW Pharmaceuticals e la sua controllata statunitense Greenwich Biosciences annunciano la pubblicazione di uno studio rivoluzionario su Epidiolex® (cannabidiolo) nel New England Journal of Medicine

- La formulazione farmaceutica del cannabidiolo ha ridotto notevolmente la frequenza degli attacchi convulsivi nei bambini in cura con molteplici...


May 25, 2017, 03:00 ET GW Pharmaceuticals und US-Tochtergesellschaft Greenwich Biosciences kündigen die Veröffentlichung einer bahnbrechenden Studie zu Epidiolex® (Cannabidiol) im New England Journal of Medicine an

- Pharmazeutische Cannabidiol-Formulierung reduziert signifikant die Häufigkeit von Krampfanfällen bei Kindern, die schlecht auf Behandlung mit...


May 25, 2017, 03:00 ET GW Pharmaceuticals y Greenwich Biosciences publican un estudio revolucionario de Epidiolex® (cannabidiol)

- GW Pharmaceuticals y su filial estadounidense Greenwich Biosciences anuncian la publicación de un estudio revolucionario de Epidiolex®...


Jan 08, 2014, 23:05 ET GW Pharmaceuticals plc Announces Pricing of U.S. Follow-On Offering of ADSs Raising $87.9 Million on NASDAQ Global Market

 GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the "Company"), a biopharmaceutical company focused on...


Dec 20, 2013, 09:07 ET GW Pharmaceuticals Files Registration Statement for Proposed Follow-On Offering

GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and...


Dec 11, 2013, 02:00 ET GW Pharmaceuticals plc Announces U.S. Patent Allowance for Use of Cannabinoids in Treating Glioma

 GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and...


Dec 02, 2013, 02:00 ET GW Pharmaceuticals to Present at the Piper Jaffray 25th Annual Health Care Conference

GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering, developing...


Nov 27, 2013, 02:00 ET GW Pharmaceuticals plc Announces Sativex® Regulatory Approval in Switzerland

 GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and...


Nov 19, 2013, 02:00 ET GW Pharmaceuticals plc Reports 2013 Q4 and Full Year Financial Results

 GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering,...


Nov 18, 2013, 13:00 ET GW Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conference

 GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering,...


Nov 15, 2013, 02:00 ET GW Pharmaceuticals Provides Update on Orphan Program in Childhood Epilepsy for Epidiolex®

GW Pharmaceuticals plc (AIM: GWP, Nasdaq: GWPH, "GW") announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug...


Nov 12, 2013, 02:00 ET GW Pharmaceuticals to Report 2013 Q4 and Full Year Financial Results and Host Conference Call on 19 November, 2013

GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and...


Nov 11, 2013, 02:00 ET GW Pharmaceuticals Commences Phase 1b/2a Clinical Trial for the Treatment of Glioblastoma Multiforme (GBM)

GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW") a biopharmaceutical company focused on discovering, developing and commercializing novel...


Oct 21, 2013, 02:00 ET GW Pharmaceuticals Announces Successful Closing of Mutual Recognition Procedure for Sativex® in France

GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and...


Oct 02, 2013, 08:10 ET GW Pharmaceuticals Announces New Sativex® Data at ECTRIMS

GW Pharmaceuticals plc (AIM: GWP, Nasdaq: GWPH, "GW") announced that data from new MS spasticity studies (clinical trial data, observational study...


Sep 23, 2013, 06:43 ET GW Pharmaceuticals Announces Agreement on Sativex® Pricing in Germany

 GW Pharmaceuticals plc (AIM: GWP, Nasdaq: GWPH, "GW") announced today that agreement for a revised mutually-acceptable reimbursement price for...


Sep 20, 2013, 02:00 ET GW Pharmaceuticals to Present at the 2013 Aegis Capital Healthcare Conference

GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW") announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present a general...


Sep 18, 2013, 02:00 ET GW Pharmaceuticals Commences Phase 1 Clinical Trial of GWP42006 as a Potential Treatment for Epilepsy

 GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW") announced today it has commenced a Phase 1 clinical trial of product candidate GWP42006...


Aug 14, 2013, 02:00 ET GW Pharmaceuticals plc Opens an Investigational New Drug Application (IND) in the United States for a Sativex® Phase 3 Clinical Program as a Treatment for Spasticity Due to Multiple Sclerosis

GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW") announced today that it has opened a Phase 3 Investigational New Drug (IND) application with...


Aug 08, 2013, 02:00 ET GW Pharmaceuticals to Present at the 33rd Annual Canaccord Genuity Growth Conference

 GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW," "the Company" or "the Group"), a biopharmaceutical company focused on discovering,...